Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
Authors' conclusion
Persistent gender disparities in SGLT2 inhibitor prescriptions highlight the need for healthcare providers worldwide to recognise potential gender biases and ensure equitable access to evidence-based CKD therapies. Addressing gender-based disparities is crucial for optimising CKD management globally.
Study context
- Population
- Individuals with chronic kidney disease (CKD) (eGFR <60 mL/min/1.73 m² at health checkups) in a large-scale real-world database in Japan
- Exposure
- Women vs men
- Outcome
- Prescription of SGLT2i
Methodological detailsreal-world database, multivariable logistic regression
- Real-world database
- Multivariable logistic regression
Main finding
SGLT2i prescription
Odds ratio
0.58
95% CI 0.55–0.62
Between Women and Men
OR 0.58 (95% CI 0.55–0.62)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Proportion of SGLT2i prescriptions after approval for CKD · September 2021 to February 2023
- Men: increased from 0.86% to 2.10%
- Women: increased from 0.34% to 0.88%
Original publication
Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study. Diabetes Obes Metab. Published 18 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →